Ma­gen­ta bags $52M Se­ries C for bone mar­row trans­plant pipeline

High-fly­ing Cam­bridge start­up Ma­gen­ta has snagged $52 mil­lion in a new fi­nanc­ing round to push for­ward the com­pa­ny’s pipeline of ther­a­pies for bone mar­row trans­plant.

The mon­ey comes in an over­sub­scribed Se­ries C round led by New York-based Cas­din Cap­i­tal, with EcorR1 Cap­i­tal, Even­tide As­set Man­age­ment, Wa­ter­mill As­set Man­age­ment and ad­di­tion­al long-term in­sti­tu­tion­al in­vestors join­ing in.

The cash will be used to ad­vance Ma­gen­ta’s port­fo­lio, in­clud­ing tar­get­ed bone mar­row trans­plant con­di­tion­ing pro­grams, stem cell mo­bi­liza­tion and stem cell ex­pan­sion pro­grams. The fund­ing will al­so push for­ward Ma­gen­ta’s most ad­vanced clin­i­cal prod­uct can­di­date, MG­TA- 456, a cell ther­a­py in Phase II tri­als in pa­tients with in­her­it­ed meta­bol­ic dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER